About This Briefing

What Peptide Care Now is

Peptide Care Now is a standing briefing on the published research into two peptides studied for immune modulation and thymic biology: thymulin and thymosin alpha-1. It sets out to make a scattered, technically dense, and frequently misrepresented literature legible — to tell a reader, in plain language and with citations, what each compound was actually studied for, in which species and models, and how far that evidence reaches.

The organizing idea is precision over breadth. Rather than skim dozens of immune-related peptides, the briefing goes deep on two compounds that map the thymus-to-immune-system axis from complementary angles — thymulin as the hormonal, zinc-dependent signal the thymus itself produces, and thymosin alpha-1 as the broader immunomodulatory peptide with a substantial, honest, and at times humbling trial record. Each compound has its own page; a comparison page sets them side by side; a single shared references list gathers every source.

How it is compiled

Three rules shape the briefing.

One — everything is anchored to the peer-reviewed literature. Each research claim carries a numbered citation — PubMed-indexed journal articles, clinical trial reports, and systematic reviews — collected on the references page. A finding drawn from a review is cited as a review. Effect sizes, trial populations, species, and routes of administration are reported as they stand in the source paper, not smoothed into generic claims.

Two — the evidence is reported at its true strength. Doses are given in the species and route in which they were studied — never scaled to humans or offered as a recommendation. Where a trial returned a null result, that result is put up front, not buried. The 2025 Phase 3 TESTS null result for thymosin alpha-1 in sepsis is no footnote here; it is a section heading ^[8].

Three — the pages are cross-referenced. Because thymulin and thymosin alpha-1 both bear on thymic output and T-cell biology, the pages link to one another so a reader can follow a shared thread — T-lymphocyte differentiation, neuroendocrine modulation — across both compounds and see where the stories converge and where they part entirely.

What it is not

Peptide Care Now is no store, no clinic, and no source of medical advice. It sells, supplies, sources, and brokers no peptide or research chemical, and holds no affiliate or referral tie to any vendor. It keeps no clinicians, diagnoses no condition, and prescribes nothing. It recommends no dose, schedule, or route of administration for anyone, and never dresses an animal-study dose as something a human should take.

The peptides here are research compounds. Neither is FDA-approved for systemic human use in the United States; thymosin alpha-1 is approved abroad under the brand name thymalfasin, but those approvals cover specific clinical indications with specific dosing labels managed by licensed clinicians in those jurisdictions. Anyone who believes they may benefit from immune-modulating therapies should consult a licensed clinician working with regulated, evidence-based options in their own jurisdiction. What the briefing offers is a calm, data-forward map of the literature — nothing more.